United States· US:0003-0894_663be5ea-b58d-43c9-8138-2d9ed0846308

ELIQUIS

A apixaban product containing apixaban, registered in United States by E.R. Squibb & Sons, L.L.C.. The same ATC class is registered in 17 of our 19 countries.

ATC B01AF02

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedELIQUISATCB01AF02REGISTER NO.US:0003-0894_663be5ea…PACKS LISTED4CHECKEDSeptember 27, 2026

Where it is registered

Apixaban is registered in 17 of 19 countries.

Countries holding a registration under ATC B01AF02 (apixaban), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 10 of them publish a price we can compare per daily dose

Apixaban · ATC B01AF02

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of apixaban costs, country by country.

Normalised to the WHO defined daily dose (10 mg), the median price runs from $3.38 in France to $7.97 in Italy — a ×2.4 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Apixaban · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • IT Italy$7.97
  • CH Switzerland$4.70
  • FR France$3.38
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
APIXABAN
Manufacturer
E.R. Squibb & Sons, L.L.C.
Country
United States (US)
ATC code
B01AF02
ATC class
Apixaban
Defined daily dose
10 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 4

  • ndc11
    0003-0894-21
  • ndc11
    0003-0894-31
  • ndc11
    0003-0894-70
  • ndc11
    0003-0894-91

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

398 interactions on record for apixaban.

Graded by severity as the source publishes them — 133 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Apixaban · interactions on record

398 records

  • 133 severe
  • 224 moderate
  • 2 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe

39 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Apixaban in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All apixaban products

Authorised across Europe · EMA

The same active substance is authorised in 31 EEA countries. Names it is sold under:

  • Austria · Abatixent, Apixaban +pharma
  • Belgium · Apixaban Ab, Apixaban Eg
  • Bulgaria · Abatixent, Apixaban
  • Cyprus · Abidalo, Apixaban
  • Czechia · Aboxoma, Apixaban
  • Germany · Abidalo, Akkirateron
  • Denmark · Apinovia, Apinovia 5 Mg Film-Coated Tablets
  • Estonia · Abatixent, Aboxoma
  • Spain · Apicassa, Apiclot
  • Finland · Apiclodem, Apixaban
  • France · Apixaban, Apixaban Aet
  • United Kingdom (Northern Ireland) · Apixaban, Apixaban Abdi
  • Greece · Abixatec, Aboxoma
  • Croatia · Abatixent, Abidalo
  • Hungary · Aboxoma, Apixaban
  • Ireland · Apixaban Abdi, Apixaban Aristo
  • Iceland · Apixaban Accord, Apixaban Krka
  • Italy · Apilion, Apixaban Abdi
  • Liechtenstein · Apixaban Accord, Eliquis
  • Lithuania · Abatixent, Aboxoma
  • Luxembourg · Apixaban Eg, Apixaban Ratiopharm
  • Latvia · Abatixent, Aboxoma
  • Malta · Abidalo, Antixara
  • Netherlands · Abatixent, Apilion
  • Norway · Apixaban Accord, Apixaban Axunio
  • Poland · Abatixent, Aboxoma
  • Portugal · Apixaban Grindeks, Apixabano Alter
  • Romania · Abatixent, Aboxoma
  • Sweden · Apixaban, Apixaban Axunio
  • Slovenia · Abatixent, Aboxoma
  • Slovakia · Aboxoma, Apixaban

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fb95420b-57d4-46cd-acb0-d91af422bfbf
GET /v1/drugs/fb95420b-57d4-46cd-acb0-d91af422bfbf?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "5",
  "substance": "APIXABAN",
  "productndc": "0003-0894",
  "dosage_form": "TABLET, FILM COATED",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA202155",
  "marketing_category": "NDA"
}

See everything about apixaban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.